Time-related improvement of survival in resectable gastric cancer: The role of Japanese-style gastrectomy with D2 lymphadenectomy and adjuvant chemotheraphy

Juan J. Grau, Ramon Palmero, Maribel Marmol, Jose Domingo-Domenech, Mariano Monzo, Jose Fuster, Oscar Vidal, Constantino Fondevila, Juan C. Garcia-Valdecasas

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Background: We investigated the change of prognosis in resected gastric cancer (RGC) patients and the role of radical surgery and adjuvant chemotherapy. Methods: We retrospectively analyze the outcome of 426 consecutive patients from 1975 to 2002, divided into 2 time-periods (TP) cohort: Before 1990 (TP1, n = 207) and 1990 or after (TP2; n = 219). Partial gastrectomy and D1-lymphadenetomy was predominant in TP1 and total gastrectomy with D2-lymphadenectomy it was in TP2. Adjuvant chemotherapy consisted of mitomycin C (MMC), 10-20 mg/m2 iv 4 courses or MMC plus Tegafur 500 mg/m2 for 6 months. Results: Positive nodes were similar in TP2/TP1 patients with 56%/59% respectively. Total gastrectomy was done in 56%/45% of TP2/TP1 respectively. Two-drug adjuvant chemotherapy was administered in 65%/18% of TP2/TP1 respectively. Survival at 5 years was 66% for TP2 versus 42% for TP1 patients (p < 0.0001). Survival by stages II, IIIA y IIIB for TP2 versus TP1 patients was 70 vs. 51% (p = 0.0132); 57 vs. 22% (p = 0.0008) y 30 vs. 15% (p = 0.2315) respectively. Multivariate analysis showed that age, stage of disease and period of treatment were independent variables. Conclusion: The global prognosis and that of some stages have improved in recent years with case RGC patients treated with surgery and adjuvant chemotherapy.

Original languageEnglish
Article number53
JournalWorld Journal of Surgical Oncology
Volume4
DOIs
StatePublished - 11 Aug 2006
Externally publishedYes

Fingerprint

Dive into the research topics of 'Time-related improvement of survival in resectable gastric cancer: The role of Japanese-style gastrectomy with D2 lymphadenectomy and adjuvant chemotheraphy'. Together they form a unique fingerprint.

Cite this